Alliqua to Launch Biovance(R) Human Amniotic Membrane Allograft Product Licensed From Celgene

Alliqua to Launch Biovance(R) Human Amniotic Membrane Allograft Product
Licensed From Celgene

Biovance Data Will Also Be Presented at Spring 2014 Symposium on Advanced
Wound Care in Orlando

LANGHORNE, Pa., April 23, 2014 (GLOBE NEWSWIRE) -- Alliqua, Inc. (Nasdaq:ALQA)
("Alliqua" or "the Company"), a provider of advanced wound care products, will
launch its Biovance^® human amniotic membrane allograft product at Booth #1208
at the Spring 2014 Symposium on Advanced Wound Care to be held at the Gaylord
Palms Hotel and Convention Center in Orlando, Florida on April 23-27.

Biovance was originally developed by, and is currently being manufactured
through a supply agreement with, Celgene Cellular Therapeutics ("CCT"), a
subsidiary of Celgene Corporation, to assist wound care specialists,
physicians and nurses, as well as vascular, plastic and general surgeons, in
the treatment of a wide variety of complex, acute, chronic, recalcitrant, full
and partial thickness wound types.

With the right to develop and market Biovance, Alliqua has entered into one of
the fastest-growing areas of wound care, which involves regenerative medicine.
Alliqua will commence sales of Biovance immediately following the Symposium
via its team of direct sales representatives.

Additionally, Terry Treadwell, MD and Donna Walker, LPN (Institute for
Advanced Wound Care, Montgomery, AL) have authored a poster that will be on
display during SAWC (CR_049) titled "Treatment of Second Degree Burns with
Dehydrated, Decellularized Amniotic Membrane (Biovance) versus a
Nanocrystalline Silver Dressing." The poster reviews time to healing and
visual cosmetic appearance of the burn scar with Biovance compared to silver
dressing in patients with second-degree burns.

Perry Karsen, CEO of Celgene Cellular Therapeutics, remarked, "We have great
confidence in Alliqua and its management team in bringing Biovance to patients
throughout the United States."

On April 14, 2014, Celgene invested $5,000,000 in Alliqua as part of the
Company's previously announced private placement that resulted in gross
proceeds to the Company of $15 million.

David Johnson, CEO of Alliqua, said, "The SAWC meeting is the ideal venue at
which to launch our Biovance product and to convey its natural benefits to the
wound care community. The launch of Biovance marks a major milestone for
Alliqua, representing a key application of regenerative medicine for advanced
wound care and an important addition to Alliqua's wound care portfolio. We are
confident that wound care specialists and their patients will be impressed
with the value this human amniotic membrane allograft brings to their wound
care arsenal."

The Symposium on Advanced Wound Care is the largest annual gathering of wound
care clinicians in the U.S. It provides clinical education and information to
physicians, podiatrists, nurses, physical therapists and allied health
professionals dedicated to the advancement of wound care and healing. For more
information, visit http://www.sawc.net/spring/.

About Alliqua, Inc.

Alliqua is a provider of advanced wound care solutions. Through its extensive
sales and distribution network, together with its proprietary products,
Alliqua provides a suite of technological solutions to enhance the wound care
practitioner's ability to deal with the challenges of healing both chronic and
acute wounds.

In addition, Alliqua can provide a custom manufacturing solution to partners
in the medical device and cosmetics industry, utilizing its proprietary
hydrogel technology. Alliqua currently markets its line of hydrogel products
for wound care under the SilverSeal^(R) and Hydress^(R) brands, as well as the
sorbion sachet S^(R) and sorbion sana^(R) wound care products. It also has the
right to develop and market the advanced wound care products Biovance^(R) and
Extracellular Matrix (ECM), as part of its agreement with Celgene Cellular
Therapeutics. Alliqua's electron beam production process, located at its
16,000 square foot GMP manufacturing facility in Langhorne, PA, allows Alliqua
to develop and custom manufacture a wide variety of hydrogels. Alliqua's
hydrogels can be customized for various transdermal applications to address
market opportunities in the treatment of wounds as well as the delivery of
numerous drugs or other agents for pharmaceutical and cosmetic industries.

For additional information, please visit http://www.alliqua.com. To receive
future press releases via email, please visit
http://ir.stockpr.com/alliqua/email-alerts. Any statements contained in this
press release regarding our ongoing research and development and the results
attained by us to-date have not been evaluated by the Food and Drug
Administration.

Legal Notice Regarding Forward-Looking Statements

This release contains forward-looking statements. Forward-looking statements
are generally identifiable by the use of words like "may," "will," "should,"
"could," "expect," "anticipate," "estimate," "believe," "intend," or "project"
or the negative of these words or other variations on these words or
comparable terminology. The reader is cautioned not to put undue reliance on
these forward-looking statements, as these statements are subject to numerous
factors and uncertainties outside of our control that can make such statements
untrue, including, but not limited to, inadequate capital, adverse economic
conditions, intense competition, lack of meaningful research results, entry of
new competitors and products, adverse federal, state and local government
regulation, termination of contracts or agreements, technological obsolescence
of our products, technical problems with our research and products, price
increases for supplies and components, inability to carry out research,
development and commercialization plans, loss or retirement of key executives
and research scientists and other specific risks. We currently have no
commercial products intended to diagnose, treat, prevent or cure any disease.
The statements contained in this press release regarding our ongoing research
and development and the results attained by us to-date have not been evaluated
by the Food and Drug Administration. There can be no assurance that further
research and development, and/or whether clinical trial results, if any, will
validate and support the results of our preliminary research and studies.
Further, there can be no assurance that the necessary regulatory approvals
will be obtained or that we will be able to develop new products on the basis
of our technologies. In addition, other factors that could cause actual
results to differ materially are discussed in our Annual Report on Form 10-K
filed with the SEC on March 24, 2014, and our most recent Form 10-Q filings
with the SEC. Investors and security holders are urged to read these documents
free of charge on the SEC's web site at http://www.sec.gov. We undertake no
obligation to publicly update or revise our forward-looking statements as a
result of new information, future events or otherwise.

CONTACT: Alliqua, Inc.
         Brian M. Posner, +1-215-702-8550
         Chief Financial Officer
         bposner@alliqua.com
         or
         Investor Relations:
         Dian Griesel Int'l.
         Cheryl Schneider, +1-212-825-3210
         cschneider@dgicomm.com
         or
         Public Relations:
         Dian Griesel Int'l.
         Susan Forman or Laura Radocaj, +1-212-825-3210
         sforman@dgicomm.com
         lradocaj@dgicomm.com

Alliqua, Inc. logo
 
Press spacebar to pause and continue. Press esc to stop.